NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders

Current Hepatology Reports

Volumn 15, Issue 2, 2016, Pages 103-112

  Sasdelli, Anna Simona ^a   Brodosi, Lucia ^a   Marchesini, Giulio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatocellular carcinoma (HCC); Non alcoholic steatohepatitis (NAFLD); Surveillance; Treatment

Indexed keywords

EID: 84991081650     PISSN: None     EISSN: 21959595     Source Type: Journal    
DOI: 10.1007/s11901-016-0297-7     Document Type: Article

References (79)

1. H.B. El-Serag K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 2007 132 7 2557 76 1:CAS:528:DC%2BD2sXnvFOgsrw%3D 10.1053/j.gastro.2007.04.061 17570226
2. M.R. Charlton J.M. Burns R.A. Pedersen K.D. Watt J.K. Heimbach R.A. Dierkhising Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 2011 141 4 1249 53 10.1053/j.gastro.2011.06.061 21726509
3. A.C. Yopp M.A. Choti Non-alcoholic steatohepatitis-related hepatocellular carcinoma: a growing epidemic? Dig Dis 2015 33 5 642 7 10.1159/000438473 26398208
4. E. Bugianesi N. Leone E. Vanni G. Marchesini F. Brunello P. Carucci et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma Gastroenterology 2002 123 1 134 40 10.1053/gast.2002.34168 12105842
5. H.O. Adami W.H. Chow O. Nyren C. Berne M.S. Linet A. Ekbom et al. Excess risk of primary liver cancer in patients with diabetes mellitus J Natl Cancer Inst 1996 88 20 1472 7 1:STN:280:DyaK28vjvVKlsA%3D%3D 10.1093/jnci/88.20.1472 8841022
6. H.B. El-Serag P.A. Richardson J.E. Everhart The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans Am J Gastroenterol 2001 96 8 2462 7 1:STN:280:DC%2BD3MvmvVKqug%3D%3D 10.1111/j.1572-0241.2001.04054.x 11513191
7. S. Schlesinger K. Aleksandrova T. Pischon M. Jenab V. Fedirko E. Trepo et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort Ann Oncol 2013 24 9 2449 55 1:STN:280:DC%2BC3snnvFyrtg%3D%3D 10.1093/annonc/mdt204 23720454 3755330
8. K. Shetty J. Chen J.H. Shin W. Jogunoori L. Mishra Pathogenesis of hepatocellular carcinoma development in non alcoholic fatty liver disease Curr Hepatol Rep 2015 14 2 119 27 10.1007/s11901-015-0260-z 26114083 Comprehensive review on the pathogenesis of hepatocellular carcinoma
9. A. Weinmann Y. Alt S. Koch C. Nelles C. Duber H. Lang et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma BMC Cancer 2015 15 210 10.1186/s12885-015-1197-x 25884354 4407550 The most recent such study
10. J.A. Marrero R.J. Fontana S. Fu H.S. Conjeevaram G.L. Su A.S. Lok Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma J Hepatol 2005 42 2 218 24 1:CAS:528:DC%2BD2MXmvFWjsw%3D%3D 10.1016/j.jhep.2004.10.005 15664247
11. D.L. White F. Kanwal H.B. El-Serag Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review Clin Gastroenterol Hepatol 2012 10 12 1342 59 10.1016/j.cgh.2012.10.001 23041539 3501546 e1342
12. European Association for the Study of the Liver, European Organisation for Research Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 2012 56 4 908 43 10.1016/j.jhep.2011.12.001
13. J. Ertle A. Dechene J.P. Sowa V. Penndorf K. Herzer G. Kaiser et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis Int J Cancer 2011 128 10 2436 43 1:CAS:528:DC%2BC3MXjvVSkt70%3D 10.1002/ijc.25797 21128245
14. A. Sanyal A. Poklepovic E. Moyneur V. Barghout Population-based risk factors and resource utilization for HCC: US perspective Curr Med Res Opin 2010 26 9 2183 91 1:STN:280:DC%2BC3cjkslyhug%3D%3D 10.1185/03007995.2010.506375 20666689
15. R.J. Wong R. Cheung A. Ahmed Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S Hepatology 2014 59 6 2188 95 10.1002/hep.26986 24375711 In a large U.S. series, the study identifies NASH as the most rapidly growing indication for liver transplantation, accounting for the present and future burden of disease
16. R.J. Wong M. Aguilar R. Cheung R.B. Perumpail S.A. Harrison Z.M. Younossi et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States Gastroenterology 2015 148 3 547 55 10.1053/j.gastro.2014.11.039 25461851
17. M.S. Ascha I.A. Hanouneh R. Lopez T.A. Tamimi A.F. Feldstein N.N. Zein The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis Hepatology 2010 51 6 1972 8 10.1002/hep.23527 20209604
18. J.D. Browning K.S. Kumar M.H. Saboorian D.L. Thiele Ethnic differences in the prevalence of cryptogenic cirrhosis Am J Gastroenterol 2004 99 2 292 8 10.1111/j.1572-0241.2004.04059.x 15046220
19. E.E. Calle C. Rodriguez K. Walker-Thurmond M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 2003 348 17 1625 38 10.1056/NEJMoa021423 12711737
20. A.G. Renehan M. Tyson M. Egger R.F. Heller M. Zwahlen Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 2008 371 9612 569 78 10.1016/S0140-6736(08)60269-X 18280327
21. C. La Vecchia E. Negri A. Decarli S. Franceschi Diabetes mellitus and the risk of primary liver cancer Int J Cancer 1997 73 2 204 7 10.1002/(SICI)1097-0215(19971009)73:2<204::AID-IJC7>3.0.CO;2-# 9335443
22. M.S. Lai M.S. Hsieh Y.H. Chiu T.H. Chen Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection Hepatology 2006 43 6 1295 302 10.1002/hep.21208 16729295
23. H.B. El-Serag T. Tran J.E. Everhart Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma Gastroenterology 2004 126 2 460 8 10.1053/j.gastro.2003.10.065 14762783
24. G. Marchesini G. Forlani Diabetes and hepatocellular cancer risk: not only a matter of hyperglycemia Hepatology 2012 55 4 1298 300 10.1002/hep.25646 22461078
25. C. Wang X. Wang G. Gong Q. Ben W. Qiu Y. Chen et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies Int J Cancer 2012 130 7 1639 48 1:CAS:528:DC%2BC38Xhtl2gsbc%3D 10.1002/ijc.26165 21544812
26. J.A. Marrero R.J. Fontana G.L. Su H.S. Conjeevaram D.M. Emick A.S. Lok NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States Hepatology 2002 36 6 1349 54 10.1002/hep.1840360609 12447858
27. J.M. Regimbeau M. Colombat P. Mognol F. Durand E. Abdalla C. Degott et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma Liver Transpl 2004 10 2 Suppl 1 S69 73 10.1002/lt.20033 14762843
28. V. Paradis S. Zalinski E. Chelbi N. Guedj F. Degos V. Vilgrain et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis Hepatology 2009 49 3 851 9 10.1002/hep.22734 19115377
29. S.K. Reddy J.L. Steel H.W. Chen D.J. DeMateo J. Cardinal J. Behari et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease Hepatology 2012 55 6 1809 19 10.1002/hep.25536 22183968
30. L. Valenti B.M. Motta G. Soardo M. Iavarone B. Donati A. Sangiovanni et al. PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma PLoS One 2013 8 10 e75982 1:CAS:528:DC%2BC3sXhs1GjsrrL 10.1371/journal.pone.0075982 24155878 3796509 The study identifies PNPLA3 as a genetic factor associated with an increased risk of HCC development
31. R. Tateishi T. Okanoue N. Fujiwara K. Okita K. Kiyosawa M. Omata et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study J Gastroenterol 2015 50 3 350 60 1:CAS:528:DC%2BC2cXpvFGqs7s%3D 10.1007/s00535-014-0973-8 24929638 4352653
32. S. Mittal Y.H. Sada H.B. El-Serag F. Kanwal Z. Duan S. Temple et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population Clin Gastroenterol Hepatol 2015 13 3 594 601 e591 10.1016/j.cgh.2014.08.013 25148760 4333060 An analysis of HCC patients survival following transplantation
33. S. Mittal H.B. El-Serag Y.H. Sada F. Kanwal Z. Duan S. Temple et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 2016 14 1 124 31 1:CAS:528:DC%2BC2MXhsl2msrrE 10.1016/j.cgh.2015.07.019 26196445
34. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatology. 2016;63:827–38. Italian experience, including personal data, on HCC presentation in relation to etiology and cirrhosis at diagnosis
35. E. Hashimoto S. Yatsuji M. Tobari M. Taniai N. Torii K. Tokushige et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis J Gastroenterol 2009 44 Suppl 19 89 95 10.1007/s00535-008-2262-x 19148800
36. K. Yasui E. Hashimoto Y. Komorizono K. Koike S. Arii Y. Imai et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma Clin Gastroenterol Hepatol 2011 9 5 428 33 10.1016/j.cgh.2011.01.023 21320639 quiz e450
37. Y. Kawamura Y. Arase K. Ikeda Y. Seko N. Imai T. Hosaka et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma Am J Gastroenterol 2012 107 2 253 61 1:CAS:528:DC%2BC38XitFanu78%3D 10.1038/ajg.2011.327 22008893
38. Y.L. Liu G.L. Patman J.B. Leathart A.C. Piguet A.D. Burt J.F. Dufour et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma J Hepatol 2014 61 1 75 81 1:CAS:528:DC%2BC2cXmtlCqs7c%3D 10.1016/j.jhep.2014.02.030 24607626 Confirmatory data on the significance of PNPLA3 as a risk factor for HCC development
39. Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2015 (ePub Nov 11).
40. R.J. Wong C. Chou C.A. Bonham W. Concepcion C.O. Esquivel A. Ahmed Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data Clin Transplant 2014 28 6 713 21 10.1111/ctr.12364 24654688
41. X. Wang J. Li D.R. Riaz G. Shi C. Liu Y. Dai Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis Clin Gastroenterol Hepatol 2014 12 3 394 402 10.1016/j.cgh.2013.09.023 24076414 e391
42. K. Yasui E. Hashimoto Y. Komorizono K. Koike S. Arii Y. Imai et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma Clin Gastroenterol Hepatol 2011 9 5 428 33 10.1016/j.cgh.2011.01.023 21320639 quiz e450
43. Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol. 2013;2013604860.
44. G. Baffy E.M. Brunt S.H. Caldwell Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace J Hepatol 2012 56 6 1384 91 10.1016/j.jhep.2011.10.027 22326465
45. F. Stickel C. Hellerbrand Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications Gut 2010 59 10 1303 7 1:CAS:528:DC%2BC3cXhtlWhsb%2FI 10.1136/gut.2009.199661 20650925
46. J. Fukushima Y. Kamada H. Matsumoto Y. Yoshida H. Ezaki T. Takemura et al. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization Hepatol Res 2009 39 7 724 38 1:CAS:528:DC%2BD1MXhtVSnu7%2FF 10.1111/j.1872-034X.2009.00509.x 19473437
47. N.K. Saxena D. Sharma X. Ding S. Lin F. Marra D. Merlin et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells Cancer Res 2007 67 6 2497 507 1:CAS:528:DC%2BD2sXivV2gu7s%3D 10.1158/0008-5472.CAN-06-3075 17363567 2925446
48. M. Dalamaga K.N. Diakopoulos C.S. Mantzoros The role of adiponectin in cancer: a review of current evidence Endocr Rev 2012 33 4 547 94 1:CAS:528:DC%2BC38XhtlGgtLfM 10.1210/er.2011-1015 22547160 3410224
49. M. Vinciguerra F. Carrozzino M. Peyrou S. Carlone R. Montesano R. Benelli et al. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN J Hepatol 2009 50 6 1132 41 1:CAS:528:DC%2BD1MXlslWmsrs%3D 10.1016/j.jhep.2009.01.027 19398230
50. H. Malhi S.F. Bronk N.W. Werneburg G.J. Gores Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis J Biol Chem 2006 281 17 12093 101 1:CAS:528:DC%2BD28Xjslensb0%3D 10.1074/jbc.M510660200 16505490
51. H. Chettouh M. Lequoy L. Fartoux C. Vigouroux C. Desbois-Mouthon Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma Liver Int 2015 35 10 2203 17 1:CAS:528:DC%2BC2MXhs1Sltr7I 10.1111/liv.12903 26123841
52. J. Alexander M. Torbenson T.T. Wu M.M. Yeh Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study J Gastroenterol Hepatol 2013 28 5 848 54 10.1111/jgh.12116 23302015
53. Chun YS, Huang M, Rink L, Von Mehren M. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study. World J Surg Oncol. 2014;12231.
54. J. Aron-Wisnewsky B. Gaborit A. Dutour K. Clement Gut microbiota and non-alcoholic fatty liver disease: new insights Clin Microbiol Infect 2013 19 4 338 48 1:CAS:528:DC%2BC3sXkt1Ggs7c%3D 10.1111/1469-0691.12140 23452163
55. S. De Minicis C. Rychlicki L. Agostinelli S. Saccomanno C. Candelaresi L. Trozzi et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice Hepatology 2014 59 5 1738 49 10.1002/hep.26695 23959503
56. V. Fedirko T. Duarte-Salles C. Bamia A. Trichopoulou K. Aleksandrova D. Trichopoulos et al. Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study Hepatology 2014 60 4 1222 30 1:CAS:528:DC%2BC2cXhs1WlurnJ 10.1002/hep.27079 24644045
57. J.B. Wang C.C. Abnet W. Chen S.M. Dawsey J.H. Fan L.Y. Yin et al. Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study Br J Cancer 2013 109 7 1997 2004 1:CAS:528:DC%2BC3sXhsVSksrnO 10.1038/bjc.2013.546 24008664 3790191
58. C. Pirazzi L. Valenti B.M. Motta P. Pingitore K. Hedfalk R.M. Mancina et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells Hum Mol Genet 2014 23 15 4077 85 1:CAS:528:DC%2BC2cXhtFeitbjM 10.1093/hmg/ddu121 24670599 4082369
59. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 2011 365 12 1118 27 1:CAS:528:DC%2BC3MXht1WqtrnL 10.1056/NEJMra1001683 21992124
60. J.M. Llovet C. Bru J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 1999 19 3 329 38 1:STN:280:DyaK1Mvks1Grsg%3D%3D 10.1055/s-2007-1007122 10518312
61. M. Iavarone G. Cabibbo F. Piscaglia C. Zavaglia A. Grieco E. Villa et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy Hepatology 2011 54 6 2055 63 1:CAS:528:DC%2BC3MXhsFCqsLrE 10.1002/hep.24644 21898496
62. M. Buzzai R.G. Jones R.K. Amaravadi J.J. Lum R.J. DeBerardinis F. Zhao et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth Cancer Res 2007 67 14 6745 52 1:CAS:528:DC%2BD2sXnslOju7s%3D 10.1158/0008-5472.CAN-06-4447 17638885
63. M. Kohjima N. Higuchi M. Kato K. Kotoh T. Yoshimoto T. Fujino et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease Int J Mol Med 2008 21 4 507 11 1:CAS:528:DC%2BD1cXkslKqtrs%3D 18360697
64. J.M. Evans L.A. Donnelly A.M. Emslie-Smith D.R. Alessi A.D. Morris Metformin and reduced risk of cancer in diabetic patients BMJ 2005 330 7503 1304 5 10.1136/bmj.38415.708634.F7 15849206 558205
65. A. Bhat G. Sebastiani M. Bhat Systematic review: preventive and therapeutic applications of metformin in liver disease World J Hepatol 2015 7 12 1652 9 10.4254/wjh.v7.i12.1652 26140084 4483546 Comprehensive review on metfoirmin use in hepatic malignancies
66. X. Zhang W.S. Harmsen T.A. Mettler W.R. Kim R.O. Roberts T.M. Therneau et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes Hepatology 2014 60 6 2008 16 1:CAS:528:DC%2BC2cXitVCis7%2FO 10.1002/hep.27199 24798175 4218882 Examines beneficial effects of metformin in subjects with liver disease
67. S. Singh P.P. Singh A.G. Singh M.H. Murad W. Sanchez Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis Gastroenterology 2013 144 2 323 32 1:CAS:528:DC%2BC38XhvVaqu7jL 10.1053/j.gastro.2012.10.005 23063971
68. T. Teratani K. Tomita T. Suzuki T. Oshikawa H. Yokoyama K. Shimamura et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells Gastroenterology 2012 142 1 152 64 1:CAS:528:DC%2BC3MXhs1Ght7fM 10.1053/j.gastro.2011.09.049 21995947 e110
69. G. Musso R. Gambino M. Cassader Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis Prog Lipid Res 2013 52 1 175 91 1:CAS:528:DC%2BC38XhvFSktrvK 10.1016/j.plipres.2012.11.002 23206728
70. N. Mazzella L.M. Ricciardi A. Mazzotti G. Marchesini The role of medications for the management of patients with NAFLD Clin Liver Dis 2014 18 1 73 89 10.1016/j.cld.2013.09.005 24274866
71. P.C. Calder Polyunsaturated fatty acids and inflammation Prostaglandins Leukot Essent Fatty Acids 2006 75 3 197 202 1:CAS:528:DC%2BD28XptFChtrc%3D 10.1016/j.plefa.2006.05.012 16828270
72. J. Monteiro M. Leslie M.H. Moghadasian B.M. Arendt J.P. Allard D.W. Ma The role of n-6 and n-3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease Food Funct 2014 5 3 426 35 1:CAS:528:DC%2BC2cXjt1yqurY%3D 10.1039/c3fo60551e 24496399
73. Koh WP. Dan YY. Jin A, Wang R, Yuan JM. Dietary fatty acids and risk of hepatocellular carcinoma in the Singapore Chinese health study. Liver Int. 2015. doi:10.1111/liv.12978.
74. T. Duarte-Salles V. Fedirko M. Stepien K. Aleksandrova C. Bamia P. Lagiou et al. Dietary fat, fat subtypes and hepatocellular carcinoma in a large European cohort Int J Cancer 2015 137 11 2715 28 1:CAS:528:DC%2BC2MXhtFWmur3N 10.1002/ijc.29643 26081477 An analysis on the relationship between fat intake and HCC development in the large EPIC cohort
75. W.Q. Li Y. Park K.A. McGlynn A.R. Hollenbeck P.R. Taylor A.M. Goldstein et al. Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study Hepatology 2014 60 2 588 97 1:CAS:528:DC%2BC2cXht1WmsLzJ 10.1002/hep.27160 24715615 4110163
76. N. Chalasani Z. Younossi J.E. Lavine A.M. Diehl E.M. Brunt K. Cusi et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 2012 142 7 1592 609 10.1053/j.gastro.2012.04.001 22656328
77. J. Dyson B. Jaques D. Chattopadyhay R. Lochan J. Graham D. Das et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team J Hepatol 2014 60 1 110 7 10.1016/j.jhep.2013.08.011 23978719
78. G. Zoppini U. Fedeli N. Gennaro M. Saugo G. Targher E. Bonora Mortality from chronic liver diseases in diabetes Am J Gastroenterol 2014 109 7 1020 5 10.1038/ajg.2014.132 24890439
79. D. Prati E. Taioli A. Zanella E. Della Torre S. Butelli E. Del Vecchio et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels Ann Intern Med 2002 137 1 1 10 1:CAS:528:DC%2BD38Xls1entbc%3D 10.7326/0003-4819-137-1-200207020-00006 12093239